A detailed history of Black Rock Inc. transactions in Clene Inc. stock. As of the latest transaction made, Black Rock Inc. holds 83,451 shares of CLNN stock, worth $367,184. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,451
Previous 180,009 53.64%
Holding current value
$367,184
Previous $77,000 61.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.31 - $0.44 $29,932 - $42,485
-96,558 Reduced 53.64%
83,451 $30,000
Q1 2024

May 10, 2024

SELL
$0.28 - $0.53 $79,578 - $150,630
-284,209 Reduced 61.22%
180,009 $77,000
Q4 2023

Feb 13, 2024

BUY
$0.26 - $0.55 $8,453 - $17,882
32,513 Added 7.53%
464,218 $139,000
Q3 2023

Nov 13, 2023

BUY
$0.46 - $0.87 $109,346 - $206,806
237,709 Added 122.53%
431,705 $215,000
Q2 2023

Aug 11, 2023

BUY
$0.78 - $1.22 $5,370 - $8,399
6,885 Added 3.68%
193,996 $170,000
Q1 2023

May 12, 2023

BUY
$0.95 - $1.62 $1,772 - $3,022
1,866 Added 1.01%
187,111 $211,000
Q4 2022

Feb 13, 2023

BUY
$0.92 - $40.2 $1,144 - $50,008
1,244 Added 0.68%
185,245 $185,000
Q3 2022

Nov 14, 2022

SELL
$0.33 - $73.0 $882 - $195,275
-2,675 Reduced 1.43%
184,001 $516,000
Q2 2022

Aug 12, 2022

SELL
$2.1 - $4.12 $1.98 Million - $3.89 Million
-944,485 Reduced 83.5%
186,676 $471,000
Q1 2022

May 12, 2022

SELL
$2.42 - $4.42 $35,150 - $64,200
-14,525 Reduced 1.27%
1,131,161 $4.46 Million
Q4 2021

Feb 10, 2022

BUY
$3.95 - $7.53 $315,842 - $602,098
79,960 Added 7.5%
1,145,686 $4.7 Million
Q3 2021

Nov 09, 2021

SELL
$6.83 - $13.58 $761,811 - $1.51 Million
-111,539 Reduced 9.47%
1,065,726 $7.28 Million
Q2 2021

Aug 11, 2021

BUY
$6.98 - $13.33 $8.22 Million - $15.7 Million
1,177,265 New
1,177,265 $13.2 Million

Others Institutions Holding CLNN

About Clene Inc.


  • Ticker CLNN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,502,000
  • Market Cap $279M
  • Description
  • Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...
More about CLNN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.